Morgan Stanley has identified several small and mid-cap (SMID) biotech companies with strong potential, driven by promising pipelines, commercial viability, and upcoming regulatory milestones. Argenx, BeOne Medicines, BridgeBio, Compass Pathways, Crinetics, and enGene are highlighted for their innovative therapies and strategic positioning within the competitive biotech sector. Investors are cautioned that these smaller companies carry higher risks despite their growth prospects.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Top SMID Cap Biotech Stocks to Watch According to Morgan Stanley
Morgan Stanley has identified several small and mid-cap (SMID) biotech companies with strong potential, driven by promising pipelines, commercial viability, and upcoming regulatory milestones. Argenx, BeOne Medicines, BridgeBio, Compass Pathways, Crinetics, and enGene are highlighted for their innovative therapies and strategic positioning within the competitive biotech sector. Investors are cautioned that these smaller companies carry higher risks despite their growth prospects.